TW200515909A - Solid amorphous dispersions of an MTP inhibitor for treatment of obesity - Google Patents
Solid amorphous dispersions of an MTP inhibitor for treatment of obesityInfo
- Publication number
- TW200515909A TW200515909A TW093134701A TW93134701A TW200515909A TW 200515909 A TW200515909 A TW 200515909A TW 093134701 A TW093134701 A TW 093134701A TW 93134701 A TW93134701 A TW 93134701A TW 200515909 A TW200515909 A TW 200515909A
- Authority
- TW
- Taiwan
- Prior art keywords
- obesity
- treatment
- solid amorphous
- mtp inhibitor
- amorphous dispersions
- Prior art date
Links
- 239000006185 dispersion Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- TUOSYWCFRFNJBS-BHVANESWSA-N dirlotapide Chemical compound O=C([C@@H](NC(=O)C=1N(C2=CC=C(NC(=O)C=3C(=CC=CC=3)C=3C=CC(=CC=3)C(F)(F)F)C=C2C=1)C)C=1C=CC=CC=1)N(C)CC1=CC=CC=C1 TUOSYWCFRFNJBS-BHVANESWSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51993103P | 2003-11-14 | 2003-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200515909A true TW200515909A (en) | 2005-05-16 |
Family
ID=34590458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093134701A TW200515909A (en) | 2003-11-14 | 2004-11-12 | Solid amorphous dispersions of an MTP inhibitor for treatment of obesity |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080293801A1 (https=) |
| EP (1) | EP1696887A1 (https=) |
| JP (1) | JP2007511500A (https=) |
| KR (1) | KR20060096076A (https=) |
| CN (1) | CN1878538A (https=) |
| AR (1) | AR048206A1 (https=) |
| AU (1) | AU2004289110A1 (https=) |
| BR (1) | BRPI0416596A (https=) |
| CA (1) | CA2545443A1 (https=) |
| CO (1) | CO5690536A2 (https=) |
| IL (1) | IL175372A0 (https=) |
| MX (1) | MXPA06005489A (https=) |
| NO (1) | NO20062778L (https=) |
| NZ (1) | NZ546677A (https=) |
| TW (1) | TW200515909A (https=) |
| WO (1) | WO2005046644A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE449776T1 (de) | 2005-12-15 | 2009-12-15 | Hoffmann La Roche | Pyrroloä2,3-cüpyridinderivate |
| WO2008090198A1 (en) * | 2007-01-25 | 2008-07-31 | Janssen Pharmaceutica Nv | Use of mtp inhibitors for increasing levels of satiety hormones |
| CN102781914B (zh) * | 2010-01-06 | 2014-09-17 | 武田药品工业株式会社 | 吲哚衍生物 |
| US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
| EP3861989A1 (en) * | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
| US12453728B1 (en) | 2024-08-08 | 2025-10-28 | Redux Therapeutics, Llc | Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4884235A (en) * | 1988-07-19 | 1989-11-28 | Thiele Alfred A | Micromagnetic memory package |
| KR0182801B1 (ko) * | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5340591A (en) * | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE19504832A1 (de) * | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| SK287806B6 (sk) * | 2001-06-28 | 2011-10-04 | Pfizer Products Inc. | Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B) |
| AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
-
2004
- 2004-11-01 WO PCT/IB2004/003581 patent/WO2005046644A1/en not_active Ceased
- 2004-11-01 EP EP04798760A patent/EP1696887A1/en not_active Withdrawn
- 2004-11-01 KR KR1020067009334A patent/KR20060096076A/ko not_active Ceased
- 2004-11-01 BR BRPI0416596-9A patent/BRPI0416596A/pt not_active IP Right Cessation
- 2004-11-01 NZ NZ546677A patent/NZ546677A/en unknown
- 2004-11-01 CA CA002545443A patent/CA2545443A1/en not_active Abandoned
- 2004-11-01 JP JP2006538977A patent/JP2007511500A/ja not_active Abandoned
- 2004-11-01 CN CNA2004800334168A patent/CN1878538A/zh active Pending
- 2004-11-01 US US10/595,732 patent/US20080293801A1/en not_active Abandoned
- 2004-11-01 MX MXPA06005489A patent/MXPA06005489A/es unknown
- 2004-11-01 AU AU2004289110A patent/AU2004289110A1/en not_active Abandoned
- 2004-11-12 TW TW093134701A patent/TW200515909A/zh unknown
- 2004-11-12 AR ARP040104185A patent/AR048206A1/es unknown
-
2006
- 2006-05-01 IL IL175372A patent/IL175372A0/en unknown
- 2006-05-12 CO CO06045059A patent/CO5690536A2/es unknown
- 2006-06-14 NO NO20062778A patent/NO20062778L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5690536A2 (es) | 2006-10-31 |
| AU2004289110A1 (en) | 2005-05-26 |
| JP2007511500A (ja) | 2007-05-10 |
| EP1696887A1 (en) | 2006-09-06 |
| NO20062778L (no) | 2006-08-14 |
| BRPI0416596A (pt) | 2007-01-30 |
| KR20060096076A (ko) | 2006-09-05 |
| MXPA06005489A (es) | 2006-08-11 |
| IL175372A0 (en) | 2006-09-05 |
| CN1878538A (zh) | 2006-12-13 |
| CA2545443A1 (en) | 2005-05-26 |
| US20080293801A1 (en) | 2008-11-27 |
| AR048206A1 (es) | 2006-04-12 |
| NZ546677A (en) | 2008-11-28 |
| WO2005046644A1 (en) | 2005-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
| ATE325119T1 (de) | 3-substituierte oxindol-beta-3-agonisten | |
| BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
| BR0317715A (pt) | Composições e processos de uso de collajolie | |
| MXPA04006650A (es) | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo. | |
| BR0317819A (pt) | Aparelho para acesso restrito do navegador dentro de um dispositivo de comunicação sem fio e método para o mesmo | |
| AU2003303199A1 (en) | Generation of efficacy, toxicity and disease signatures and methods of use thereof | |
| BR0208317A (pt) | Inibidor de hidrato de gás | |
| IL165280A (en) | 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors | |
| MXPA05006629A (es) | Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador. | |
| ATE390922T1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| TW200515909A (en) | Solid amorphous dispersions of an MTP inhibitor for treatment of obesity | |
| IL162052A (en) | Indole compounds that inhibit phospholipase a2 cytosolic, methods for their preparation and uses | |
| TW200508199A (en) | Novel compound | |
| AU2003300309A1 (en) | Polymer dispersions and methods of making | |
| EP1569634B8 (en) | Use of a ppar-alpha agonist and metformin for the treatment of obesity | |
| PT1441708E (pt) | Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo | |
| ATE299703T1 (de) | Mmp-hemmer bei bindegewebserweichung | |
| GEP20084462B (en) | Association between a ppar igand and an antioxidant agent and use thereof for treating obesity | |
| PL1622882T3 (pl) | Sposób wytwarzania N-(1-oksopentylo)-N-[[2’-(IH-tetrazol-5-ilo)[I,I’-bifenyl]-4-ylo]metylo]-L-waliny (walsartan) | |
| BRPI0416482A (pt) | componente sólido de catalisador para a (co) polimerização de etileno, processo para a preparação de um componente sólido, e, catalisador e processo para a (co) polimerização de etileno | |
| WO2005042022A3 (en) | Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist | |
| CR9008A (es) | Nuevo procedimiento y compuestos intermedios de preparacion de derivados de n-(1-benzhidril-azetidin-3-il)-n-fenilmetilsulfonamida | |
| AU2003247590A1 (en) | Methods of treating waste slurry in animal waste lagoons | |
| WO2006083710A3 (en) | Use of 5-ht4 agonist for treating delayed gastric emptying which may be induced by a proton pump inhibitor |